Is Bluejay Diagnostics Inc. Common Stock a good investment? Bluejay Diagnostics Inc. Common Stock (BJDX) is currently trading at 1.02 USD.
In terms of valuation, the stock trades at a P/E ratio of 0.00. This relatively low multiple may signal that Bluejay Diagnostics Inc. Common Stock is undervalued compared to historical market norms.
Earnings Schedule: Bluejay Diagnostics Inc. Common Stock is expected to release its next earnings report on Aug. 19, 2026. The market consensus estimate for Forward EPS is -0.32.
No, it does not currently pay a dividend.
Bluejay Diagnostics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
The next earnings date is projected to be Aug. 19, 2026. The company currently has a trailing EPS of -3.74.
Bluejay Diagnostics, Inc. operates as a medical diagnostics company. It offers Symphony technology platform which consists of an analyzer and single-use protein detection cartridges that are designed to provide measurements of key diagnostic biomarkers found in blood; and Symphony analyzer used to orchestrate sample processing of whole blood, plasma, serum, etc., biomarker isolation, and immunoassay preparation using non-contact centrifugal force. The company also develops Symphony IL-6 tests for the monitoring of disease progression in critical care settings. In addition, it develops additional tests for Symphony, such as tests for myocardial infraction and congestive heart failure, as well as other tests using the Symphony platform. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
| Split Date | Split Ratio to 1 |
|---|---|
| July 24, 2023 | 0.050000 |
| June 20, 2024 | Needs review |
| Nov. 18, 2024 | 0.020000 |
| Jan. 29, 2026 | 0.250000 |
Community Discussion